Volume 14, Issue 10, Pages (September 2013)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 17, Issue 11, Pages (November 2016)

Volume 14, Issue 12, Pages (November 2013)

Volume 370, Issue 9586, Pages (August 2007)

Volume 385, Issue 9980, Pages (May 2015)

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Volume 380, Issue 9846, Pages (September 2012)

Volume 17, Issue 12, Pages (December 2016)

Volume 16, Issue 2, Pages (February 2015)

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9323, Pages (June 2002)

Volume 12, Issue 11, Pages (October 2011)

Volume 378, Issue 9785, Pages (July 2011)

Volume 376, Issue 9734, Pages (July 2010)

Volume 14, Issue 9, Pages (August 2013)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 13, Issue 12, Pages (December 2012)

Volume 373, Issue 9666, Pages (March 2009)

Volume 16, Issue 13, Pages (October 2015)

Volume 376, Issue 9734, Pages (July 2010)

Volume 366, Issue 9482, Pages (July 2005)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9677, Pages (May 2009)

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Aspirin in the prevention of cancer – Author's reply

Volume 9, Issue 9, Pages (September 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Volume 12, Issue 7, Pages (July 2011)

Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled.

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Volume 378, Issue 9785, Pages (July 2011)

Volume 13, Issue 12, Pages (December 2012)

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma.

Volume 6, Issue 6, Pages (June 2005)

Volume 19, Issue 10, Pages (October 2018)

Volume 14, Issue 6, Pages (May 2013)

Volume 9, Issue 9, Pages (September 2008)

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 385, Issue 9962, Pages (January 2015)

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled,

Volume 372, Issue 9647, Pages (October 2008)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma.

Volume 381, Issue 9880, Pages (May 2013)

Volume 13, Issue 9, Pages (September 2012)

Volume 14, Issue 6, Pages (May 2013)

Volume 5, Issue 4, Pages (April 2018)

Volume 375, Issue 9726, Pages (May 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Volume 375, Issue 9715, Pages (February 2010)

Volume 14, Issue 9, Pages (August 2013)

Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002 Antonius.

Stem cell transplantation

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Volume 383, Issue 9930, Pages (May 2014)

Treatment versus Transplant for Challenging Hematologic Disorders

Volume 371, Issue 9617, Pages (March 2008)

Mary Eapen Biology of Blood and Marrow Transplantation

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Presentation transcript:

Volume 14, Issue 10, Pages 999-1008 (September 2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial Prof Dr Susan G Kreissman, MD, Prof Robert C Seeger, MD, Prof Katherine K Matthay, MD, Wendy B London, PhD, Prof Richard Sposto, PhD, Prof Stephan A Grupp, MD, Prof Daphne A Haas-Kogan, MD, Prof Michael P LaQuaglia, MD, Prof Alice L Yu, MD, Prof Lisa Diller, MD, Allen Buxton, MS, Prof Julie R Park, MD, Prof Susan L Cohn, MD, Prof John M Maris, MD, Prof C Patrick Reynolds, MD, Prof Judith G Villablanca, MD The Lancet Oncology Volume 14, Issue 10, Pages 999-1008 (September 2013) DOI: 10.1016/S1470-2045(13)70309-7 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Treatment schema PBSC=peripheral blood stem cells. AHSCT=autologous haemopoietic stem-cell transplantation. CEM=carboplatin, etoposide, and melphalan. GFR=glomerular filtration rate. AUC=area under the curve. G-CSF=granulocyte colony-stimulating factor. ANC=absolute neutrophil count. MIBG=123I or 131I- meta-iodobenzylguanidine. The Lancet Oncology 2013 14, 999-1008DOI: (10.1016/S1470-2045(13)70309-7) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Trial profile *372 patients (192 non-purged, 180 purged) received a transplant, including those who received the PBSC product to which they were allocated (randomised) and those who were crossovers. † One additional patient who received a transplant was retrospectively (post-transplant) determined by the treating institution to have had progressive disease at the end of induction; thus table 1 presents a total of 38 patients in the purged group with end of induction progressive disease. ‡Patients alive at last contact were censored in survival analysis. The Lancet Oncology 2013 14, 999-1008DOI: (10.1016/S1470-2045(13)70309-7) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 Event-free survival and overall survival (A) Event-free survival for intention-to-treat population from time of enrolment or randomisation. (B) Overall survival for intention-to-treat population from time of enrolment or randomisation. (C) Event-free survival for comparison of patients randomly assigned to purged treatment group versus patients randomly assigned to non-purged treatment group, from time of transplantation. (D) Overall survival for comparison of patients randomly assigned to purged treatment group versus patients randomly assigned to non-purged treatment group, from time of transplantation. The Lancet Oncology 2013 14, 999-1008DOI: (10.1016/S1470-2045(13)70309-7) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 Event-free survival and overall survival by TLDA test results (A) Event-free survival. (B) Overall survival. TLDA=TaqMan low density array. PBSC=peripheral blood stem cells. The Lancet Oncology 2013 14, 999-1008DOI: (10.1016/S1470-2045(13)70309-7) Copyright © 2013 Elsevier Ltd Terms and Conditions